🇩🇰 Bactolife secures over €30 million in Series B funding to commercialize innovative binding proteins

Copenhagen, Kingdom of Denmark – 6 January, 2026

Bactolife, a pioneering company in the field of gut health solutions, has successfully raised over EUR 30 million in its Series B investment round. The funding will enable the company to commercialize its innovation Binding Proteins, a new food, feed and dietary supplement ingredient, and execute its human study program, aimed at transforming human and animal health for proactive health management.

This significant financing round was led by Cross Border Impact Ventures (CBIV) and EIFO (Danish Export and Investment Fund), alongside continued support from existing investors Novo Holdings and Athos. With the backing of cornerstone investors, Bactolife is now poised to launch its first Binding Protein products under the ingredient brand, Helm™ for human health in the United States in 2026. The company plans to expand into Asia and Europe in the years that follow, with a strong commitment to ensuring the technology is accessible to women and children in low- and middle-income countries (LMICs).

Sebastian Søderberg, CEO of Bactolife, expressed his enthusiasm for the funding’s potential: “Today’s successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026. This funding will enable us to clinically validate, scale, and commercialize our Binding Proteins, taking Bactolife’s solutions to a broad audience. We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission. We are ready to transform gut health with novel Binding Proteins.”

The proceeds from this round will be directed toward several key areas of growth for Bactolife, including the execution of its human study program across the US, EU, Asia, and LMICs. In addition, the company plans to scale its manufacturing and supply operations to meet global demand with a strong emphasis on commercialization of both human and animal health ingredients for dietary supplements, functional food and beverages, and feed additives.

Donna Parr, Managing Partner at Cross Border Impact Ventures, highlighted the broader impact of the investment: “We are thrilled to lead Bactolife’s Series B. Bactolife’s Binding Proteins have the potential to strengthen gut resilience for mothers and children in low- and middle-income countries by providing a scalable, food-grade solution that can be integrated into everyday nutrition. At the same time, we are excited about the significant growth opportunity across North America, Europe, and Asia where the market opportunity is massive. This investment reflects our conviction that evidence-based technologies can reach massive high-growth markets, inclusive of people who need them most, and we look forward to partnering with Bactolife to accelerate clinical validation, scale manufacturing, and expand equitable access globally.”

Bactolife’s Binding Proteins mark an important step forward in gut health solutions, providing a novel approach to supporting intestinal resilience by gently binding and neutralizing unhealthy metabolites. The company is committed to making its science-backed technology available for the many, not just the few, ensuring that individuals in both developed and developing regions have access to transformative healthcare solutions.

For further information, please contact:

Bactolife A/S
Julie Rastad, SVP
[email protected]
+45 30770262

Originally published on 6 January 2026 by Bactolife.

Announcements are published as a service to readers. The sender is responsible for all content.

Announcements for publication can be submitted to [email protected].